Original ArticlesAntineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer
Section snippets
Patients
Serum samples of 61 consecutive NSCLC patients (mean age 66.9 years) with potentially curative resection treatment were obtained before receiving surgical therapy after informed consent. Histological examination revealed adenocarcinoma in 29 and squamous cell carcinoma in 32 patients. There were 21 patients with stage I disease (T1N0: 5, T2N0: 16), 11 with stage II (T1N1: 2, T2N1: 9), 20 patients had stage IIIA (T3N0: 3, T3N1: 4, T1N2: 2, T2N2: 7, T3N2: 4), and 9 patients stage IIIB (1 patient
Results
A profile of the lung cancer patients studied is shown in Table 1. Autoantibodies were detectable in 33 out of 61 patients (54.1%). Of the adenocarcinoma patients, 51.7% were autoantibody positive (Ab-pos), and 56.2% of the squamous cell carcinoma patients were Ab-pos. There were no differences in the autoantibody frequency in the stages (stage I 52.3%, stage II 63.6%, stage III 51.7%). Autoantibody-positive patients had a significant better survival than autoantibody-negative patients (p =
Comment
Our study reveals a frequent humoral autoimmunity in patients with NSCLC. We were also able to show that antineural antibodies and antinuclear antibodies (ANA) are a stage-independent prognostic factor in lung non-small cell lung cancer.
The International Staging System for Lung Cancer provides a classification for the anatomic extent of NSCLC and has proven to be a predictor of prognosis 1, 2, 8. Although survival curves do confirm the relationship between the anatomy represented by the TNM
Acknowledgements
This study was supported by the “Heinrich-Dietz-Stiftung for cancer research at the Saarland University,” project-Nr. TS 117/2/97.
References (23)
- et al.
Prognosis and survival in resected lung carcinoma based on the new international staging system
J Thorac Cardiovasc Surg
(1988) Surgical treatment of lung cancer
Crit Rev Oncol Hematol
(1991)- et al.
Cancer recurrence after resectionT1N0 non-small cell lung cancer
Ann Thorac Surg
(1990) - et al.
Incidence of local recurrence and second primary tumors in resected stage I lung cancer
J Thorac Cardiovasc Surg
(1995) - et al.
Carcinogen-specific mutations in the p53 tumor suppressor gene in lung cancer
J Thorac Cardiovasc Surg
(1994) p53emergency brake and target for cancer therapy
Exp Cell Res
(1997)- et al.
Shift in the IgG subclass distribution in patients with lung cancer
Lung Cancer
(1999) - et al.
Paraneoplastic anti-Hu serumstudies on human tumor cell lines
J Neuroimmunol
(1997) A new international staging system for lung cancer
Chest
(1986)Molecular markers for the diagnosis and prognosis of lung cancer
Cancer
(1992)
The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues
Am J Pathol
Cited by (55)
Antinuclear antibodies in patients with cervical lesions and invasive cervical cancer
2019, Immunology LettersCitation Excerpt :This promotes apoptosis in pre-cancer cells with DNA abnormalities such as those with BRCA2 deficiency but not in normal cells [17,18]. Clinical data on this role is controversial [4,5,19]. Blaes et al [19] studying non-small cell lung cancer, found that the presence of ANA in the serum was associated with a better prognosis.
Safety and efficacy of PD-1 inhibitors in non–small cell lung cancer patients positive for antinuclear antibodies
2019, Lung CancerCitation Excerpt :ANA may be related to the prognosis of cancer patients. ANA-positive NSCLC patients thus showed a better survival than did ANA-negative patients after surgical therapy [18]. Moreover, PFS was found to be longer in ANA-positive NSCLC patients than in those negative for ANA after chemotherapy [11].
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses
2015, Annals of OncologyCitation Excerpt :sMUC1 was therefore measured as a potential indicator of tumor burden. Antinuclear antibodies (ANA) were examined because they have been demonstrated in patients with several types of cancer, including lung cancer [10], and are associated with improved survival in NSCLC [11]. High neutrophil/lymphocyte ratio (NLR) and high lymphocyte count were assessed because they are independent negative and positive prognostic factors, respectively, in NSCLC [12–14].
Autoantibodies against tumor-related antigens: Incidence and biologic significance
2010, Human ImmunologyA common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth
2009, Cancer LettersCitation Excerpt :Moreover, the occurrence of specific ANAs in the sera of lung cancer patients was reported as a potential predictor of lung cancer cell type and progression-free survival [155]. The presence of ANAs was also associated with a higher survival in stage III non-small lung cancer (NSCLC) patients [156]. Conversely, autoantibodies to nuclear antigens were found to correlate with early recurrence in patients with breast carcinomas [157].
New biochemical, immune and molecular markers in lung cancer: Diagnostic and prognostic opportunities
2022, Advances in Clinical and Experimental Medicine